Cartesian Therapeutics, Inc. Lease, Cost
Cartesian Therapeutics, Inc. (RNAC) reported Lease, Cost of $946.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-06
- Cartesian Therapeutics, Inc. lease, cost for the quarter ending 2026-06-30 was $946.00K, a 5.87% decline year-over-year.
- Cartesian Therapeutics, Inc. lease, cost for the quarter ending 2026-03-31 was $1.02M, a 1.70% increase year-over-year.
- Cartesian Therapeutics, Inc. lease, cost for the quarter ending 2025-12-31 was $1.10M, a 25.73% decline year-over-year.
- Cartesian Therapeutics, Inc. lease, cost for the quarter ending 2025-09-30 was $1.13M, a 5.30% decline year-over-year.
- Cartesian Therapeutics, Inc. lease, cost for fiscal 2025 was $4.23M, a 3.69% decline from fiscal 2024.
- Cartesian Therapeutics, Inc. lease, cost for fiscal 2024 was $4.39M, a 67.14% increase from fiscal 2023.
- Cartesian Therapeutics, Inc. lease, cost for fiscal 2023 was $2.63M, a 12.98% decline from fiscal 2022.
- Cartesian Therapeutics, Inc. lease, cost for fiscal 2022 was $3.02M, a 5.37% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $946.00K 10-Q · filed 2026-08-06 | $1.97M 10-Q · filed 2026-08-06 | $3.06M derived: sum of 3 quarters · filed 2026-08-06 | $4.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.02M 10-Q · filed 2026-04-30 | $2.12M derived: sum of 2 quarters · filed 2026-04-30 | $3.24M derived: sum of 3 quarters · filed 2026-04-30 | $4.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.23M derived: sum of 2 quarters · filed 2026-03-09 | $3.23M derived: sum of 3 quarters · filed 2026-08-06 | $4.23M 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.13M 10-Q · filed 2025-11-06 | $2.13M derived: sum of 2 quarters · filed 2026-08-06 | $3.13M 10-Q · filed 2025-11-06 | $4.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.00M 10-Q · filed 2026-08-06 | $2.01M 10-Q · filed 2026-08-06 | $3.49M derived: sum of 3 quarters · filed 2026-08-06 | $4.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.00M 10-Q · filed 2026-04-30 | $2.48M derived: sum of 2 quarters · filed 2026-04-30 | $3.67M derived: sum of 3 quarters · filed 2026-04-30 | $4.73M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.67M derived: sum of 2 quarters · filed 2026-03-09 | $3.73M derived: sum of 3 quarters · filed 2026-03-09 | $4.39M 10-K · filed 2026-03-09 |
| 2024-09-30 | $1.19M 10-Q · filed 2025-11-06 | $2.25M derived: sum of 2 quarters · filed 2025-11-06 | $2.91M 10-Q · filed 2025-11-06 | $3.52M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.06M 10-Q · filed 2025-08-07 | $1.72M 10-Q · filed 2025-08-07 | $2.33M derived: sum of 3 quarters · filed 2025-08-07 | $3.05M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $665.00K 10-Q · filed 2025-05-08 | $1.27M derived: sum of 2 quarters · filed 2025-05-08 | $1.99M derived: sum of 3 quarters · filed 2025-05-08 | $2.71M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $608.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.33M derived: sum of 2 quarters · filed 2025-03-13 | $2.04M derived: sum of 3 quarters · filed 2025-03-13 | $2.63M 10-K · filed 2025-03-13 |
| 2023-09-30 | $718.00K 10-Q · filed 2024-11-07 | $1.44M derived: sum of 2 quarters · filed 2024-11-07 | $2.02M 10-Q · filed 2024-11-07 | $2.82M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $717.00K 10-Q · filed 2024-08-08 | $1.30M 10-Q · filed 2024-08-08 | $2.11M derived: sum of 3 quarters · filed 2024-08-08 | $2.88M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $586.00K 10-Q · filed 2024-05-08 | $1.39M derived: sum of 2 quarters · filed 2024-05-08 | $2.17M derived: sum of 3 quarters · filed 2024-05-08 | $2.88M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $803.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $1.58M derived: sum of 2 quarters · filed 2024-03-07 | $2.29M derived: sum of 3 quarters · filed 2024-03-07 | $3.02M 10-K · filed 2024-03-07 |
| 2022-09-30 | $777.00K 10-Q · filed 2023-11-13 | $1.49M derived: sum of 2 quarters · filed 2023-11-13 | $2.22M 10-Q · filed 2023-11-13 | $3.07M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $712.00K 10-Q · filed 2023-08-17 | $1.44M 10-Q · filed 2023-08-17 | $2.29M derived: sum of 3 quarters · filed 2024-03-07 | $2.94M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | $729.00K 10-Q · filed 2023-05-04 | $1.58M derived: sum of 2 quarters · filed 2024-03-07 | $2.22M derived: sum of 3 quarters · filed 2024-03-07 | $2.86M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | $853.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $1.49M derived: sum of 2 quarters · filed 2024-03-07 | $2.13M derived: sum of 3 quarters · filed 2024-03-07 | $2.87M 10-K · filed 2024-03-07 |
| 2021-09-30 | $641.00K 10-Q · filed 2022-11-03 | $1.28M derived: sum of 2 quarters · filed 2022-11-03 | $2.01M 10-Q · filed 2022-11-03 | $2.65M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $638.00K 10-Q · filed 2022-08-08 | $1.37M 10-Q · filed 2022-08-08 | $2.01M derived: sum of 3 quarters · filed 2023-03-02 | $2.64M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $735.00K 10-Q · filed 2022-05-05 | $1.37M derived: sum of 2 quarters · filed 2023-03-02 | $2.00M derived: sum of 3 quarters · filed 2023-03-02 | $2.79M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $636.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $1.27M derived: sum of 2 quarters · filed 2023-03-02 | $2.06M derived: sum of 3 quarters · filed 2023-03-02 | $2.73M 10-K · filed 2023-03-02 |
| 2020-09-30 | $632.00K 10-Q · filed 2021-11-09 | $1.42M derived: sum of 2 quarters · filed 2021-11-09 | $2.09M 10-Q · filed 2021-11-09 | $2.64M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $790.00K 10-Q · filed 2021-08-12 | $1.46M 10-Q · filed 2021-08-12 | $2.01M derived: sum of 3 quarters · filed 2022-03-10 | $2.56M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $673.00K 10-Q · filed 2021-05-13 | $1.22M derived: sum of 2 quarters · filed 2022-03-10 | $1.77M derived: sum of 3 quarters · filed 2022-03-10 | $2.33M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $547.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.10M derived: sum of 2 quarters · filed 2022-03-10 | $1.66M derived: sum of 3 quarters · filed 2022-03-10 | $2.21M 10-K · filed 2022-03-10 |
| 2019-09-30 | $555.00K 10-Q · filed 2020-11-05 | $1.11M derived: sum of 2 quarters · filed 2020-11-05 | $1.66M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $555.00K 10-Q · filed 2020-08-06 | $1.11M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $552.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |